Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- DEPO -20.4%, (also discloses opioid-related request and subpoenas),CIE -15.1%, PAA -14.4%, EVH -12.3%, (also plans to offer $175 million of its Class A common stock), SEAS -11.9%, EKSO -10.4%, MNKD -9.4%,LCI -9.4%, THC -9.2%, CAR -8.7%, DF -7.8%, RUN -7.7%, NCMI -6.7%,PLUG -6.3%, ATKR -6.1%, DQ -6%, INWK -5.7%, CHRS -4.8%, GWPH-4.8%, ATSG -4.5%, ARNA -4.1%, FRGI -3.5%, RSPP -3.3%, IHG -3.2%,GBT -2.9%, ALB -2.9%, RDNT -2.5%, MNK -2.3%, BIOS -2.3%, NVGS -2%,SMI -2%, ADES -1.8%, CVGI -1.7%, STML -1.7%, KRNT -1.6%, CRZO-1.6%, IT -1%, CVCO -0.9%, BLRX -0.9%, GTS -0.9%, IONS -0.9%, TISI-0.8%, LCUT -0.8%, .
Other news:
- BIOA -34.4% (commences public offering of common stock and warrants)
- BMRN -3.7% ( to offer $450 million aggregate principal amount of senior subordinated convertible notes due 2024)
- RDUS -2.4% (commences $300 mln offering of Convertible Senior Notes due 2024)
- COTV -2.4% (prices secondary offering by certain stockholders 10 mln shares of common stock at $37.00 per share)
- ESNT -2.2% (prices 5 mln common stock offering)
- MKC -1.4% (McCormick announces $500 mln common stock non-voting offering to fund part of its acquisition of Reckitt Benckiser's (RBGLY) Food Division)
- MYOK -1.3% (commences 3.5 mln common stock offering)
- HTZ -1.2% (following CAR results)
- JUNO -1% (certain directors and and officers are under investigations for brreaching their fiduciary duty to shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the Phase II/ROCKET trial of its leading product candidate), .
Analyst comments:
- GWPH -4.8% (downgraded to Hold at Maxim Group)
- GD -0.8% (initiated with a Underweight at Morgan Stanley), .